The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Revenue growth of $0.4 billion in Q1 was primarily driven by the execution of a long-term strategic partnership with the U.K. government for spring COVID booster campaigns.

Management attributed a 26% year-over-year reduction in adjusted cash costs to continued financial discipline and the winding down of large Phase III respiratory programs.

The company achieved a significant milestone with the EU approval of mCOMBRIAX for adults 50 and older, the world's first flu and COVID combination vaccine, marking its fourth approved product.

Strategic positioning in oncology was reinforced by the initiation of a Phase III trial for Intismeran as a monotherapy in Stage 1 lung cancer, targeting a market currently served only by surgery.

International markets accounted for approximately 80% of Q1 revenue, reflecting a shift toward long-term government contracts in the U.K., Canada, and Australia.

The $950 million litigation settlement was framed as a strategic resolution to worldwide legal disputes, though management is appealing for government contractor immunity.

Management reiterated a full-year 2026 revenue growth target of up to 10%, assuming potential COVID vaccination declines are offset by mNEXSPIKE penetration and strategic partnerships.

The financial framework assumes a geographic revenue mix of roughly 50% U.S. and 50% international for the full year, with commercial spend heavily weighted toward the second half.

Pivotal data readouts for norovirus and propionic acidemia (PA) are expected in 2026, which are critical for the company's transition to a multi-product commercial entity.

The U.S. FDA PDUFA date for the mRNA-1010 flu vaccine is set for August 5 of this year, representing a potential fifth approved product for the portfolio.

Cash and investments are projected to end 2026 between $4.5 billion and $5 billion, reflecting ongoing R&D investment and the planned $950 million litigation payment in Q3.

A $878 million charge was recognized in Q1 cost of sales related to a litigation settlement, significantly impacting GAAP net loss.

Management flagged a contingent liability of up to $1.3 billion if the Federal Circuit affirms liability under Section 1498, though they currently deem this loss 'not probable'.

The start of the methylmalonic acidemia (MMA) registrational trial has been deferred until after the pivotal readout from the PA program to optimize resource allocation.

The company noted that while geopolitical conflicts in the Middle East are being monitored, they currently see no material impact on the 2026 financial outlook.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management explained that the strong safety profile of Intismeran allows for intervention in early-stage disease where the current standard of care is 'watchful waiting' after surgery.

The goal is to provide 'IO-like protection' with a vaccine-like safety profile to prevent recurrence in patients who would otherwise receive no treatment.

Management expressed confidence in conducting the interim analysis in 2026 based on current event accrual rates.

The analysis is designed to either declare early success or continue to accrue events; notably, there is no built-in futility assessment in the current plan.

Moderna will first recognize revenue by selling the product to Merck at cost plus a markup, followed by a 50% share of the remaining profit.

This structure means Moderna's total realized contribution will likely be slightly greater than a flat 50% of the net profit.

The company is currently focused on securing national pricing and reimbursement, with significant revenue contributions expected to begin in 2027 and 2028.

The value proposition centers on reducing the administrative burden for healthcare systems by replacing two separate injections with a single product.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.